Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACEPHEN vs AMBENYL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
ACEPHEN (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, particularly COX-2, reducing prostaglandin synthesis. It has weak peripheral COX inhibition and minimal anti-inflammatory effect.
AMBENYL is a combination product containing codeine (opioid agonist) and bromodiphenhydramine (antihistamine). Codeine binds to mu-opioid receptors in the CNS, inhibiting ascending pain pathways and altering pain perception; bromodiphenhydramine antagonizes histamine H1 receptors, producing antitussive and sedative effects.
Mild to moderate pain,Fever
Cough suppression,Symptomatic relief of cough associated with colds or allergies
325-650 mg orally every 4-6 hours as needed; maximum 4 g/day.
Each 5 m L contains codeine phosphate 10 mg and diphenhydramine hydrochloride 12.5 mg. Adults: 10 m L (2 teaspoonfuls) orally every 4-6 hours as needed; maximum 40 m L per day.
Terminal elimination half-life: 1.0-1.5 hours in adults with normal renal function. Prolonged to 2-5 hours in hepatic impairment or elderly; requires dose adjustment in severe hepatic disease.
Codeine: 2.5-3.5 h (terminal) with CYP2D6 poor metabolizers up to 6 h. Guaifenesin: 1-2 h.
Acetaminophen is primarily metabolized in the liver via glucuronidation (UGT1A1, UGT1A6, UGT1A9) and sulfation (SULT1A1, SULT1A3). A minor fraction is oxidized by cytochrome P450 enzymes (CYP2E1, CYP1A2, CYP3A4) to a reactive toxic metabolite (NAPQI), which is normally detoxified by conjugation with glutathione.
Codeine is metabolized via CYP2D6 to morphine (active), CYP3A4 to norcodeine, and to a lesser extent via glucuronidation; bromodiphenhydramine is metabolized via CYP450 enzymes, primarily CYP2D6.
Renal: 90-95% as unchanged drug; tubular secretion and glomerular filtration. Biliary/fecal: <5%.
Renal: 60% unchanged codeine, 20% codeine-6-glucuronide; biliary/fecal: 20% as metabolites. Guaifenesin: renal 95% as unchanged drug and metabolites.
Approximately 10-20% bound to serum albumin; extensive tissue binding.
Codeine: 7-25% (albumin). Guaifenesin: negligible.
Apparent Vd: 0.5-0.7 L/kg (30-40 L in a 70 kg adult). Distributions into CSF and breast milk.
Codeine: 3-6 L/kg (extensive tissue distribution). Guaifenesin: 1-2 L/kg.
Oral: 85-90% (first-pass metabolism minimal). Rectal: approximately 70-80% of oral bioavailability.
Codeine: oral 90% (first-pass metabolism). Guaifenesin: oral 100% (well absorbed).
GFR 10-50 m L/min: 650 mg every 6 hours; GFR <10 m L/min: 650 mg every 8 hours.
GFR 30-50 m L/min: use with caution, reduce dose by 25-50% and monitor for CNS depression. GFR <30 m L/min: avoid use or use with extreme caution; codeine accumulation risk.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: maximum 2 g/day; Child-Pugh Class C: maximum 1 g/day.
Child-Pugh A: no adjustment needed. Child-Pugh B: use with caution, consider 50% dose reduction. Child-Pugh C: avoid use.
10-15 mg/kg/dose orally every 4-6 hours; maximum 75 mg/kg/day or 4 g/day, whichever is less.
Not recommended for children under 6 years. Children 6-12 years: 5 m L (1 teaspoonful) orally every 4-6 hours; maximum 20 m L per day. Children >12 years: adult dosing.
Start at lowest effective dose (325 mg every 6 hours); avoid exceeding 3 g/day unless closely monitored.
Initiate at 5 m L every 6 hours due to increased sensitivity to anticholinergic and CNS depressant effects; monitor for confusion, sedation, and urinary retention.
Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4,000 milligrams per day, and often involve more than one acetaminophen-containing product.
Risk of respiratory depression, especially in children; risk of opioid addiction, abuse, and misuse; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy; CYP2D6 ultra-rapid metabolizers may convert codeine to morphine at higher rates, leading to fatal respiratory depression.
Risk of severe liver injury with doses >4000 mg/day; use caution with hepatic impairment, chronic alcoholism, malnutrition, or concomitant hepatotoxic drugs; avoid exceeding recommended dose; limit use to 10 days for pain or 3 days for fever unless directed by physician; serious skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis) have occurred.
Respiratory depression; use in children <12 years contraindicated; risk of opioid-induced hyperalgesia; central nervous system depression; sedation; constipation; urinary retention; hypotension; anticholinergic effects; potential for misuse, abuse, and addiction; serotonin syndrome if used with other serotonergic drugs; adrenal insufficiency; risk of severe hypotension in volume-depleted patients; interactions with CNS depressants.
Hypersensitivity to acetaminophen or any component of the formulation; severe hepatic impairment or active liver disease.
Children <12 years; post-operative management in children <18 years after tonsillectomy/adenoidectomy; respiratory depression; acute or severe bronchial asthma; known hypersensitivity to codeine, bromodiphenhydramine, or any component; concurrent use of monoamine oxidase inhibitors (MAOIs) or within 14 days; gastrointestinal obstruction; paralytic ileus.
Alcohol: increased risk of hepatotoxicity. Avoid concurrent use. Food: no significant interaction, but taking with food may reduce minor gastrointestinal irritation.
Zolpidem absorption is delayed and reduced when taken with food, especially high-fat meals. To achieve rapid onset of sleep, take on an empty stomach. Avoid grapefruit juice as it may increase zolpidem levels.
Pregnancy Category C. First trimester: potential risk of neural tube defects and orofacial clefts (limited human data, animal studies show embryotoxicity). Second and third trimesters: NSAID exposure associated with oligohydramnios, premature ductus arteriosus constriction, and fetal renal impairment. Avoid in third trimester.
FDA Pregnancy Category C. First trimester: Limited data; potential for fetal malformations (cleft palate, cardiac defects) based on animal studies with high-dose antihistamines. Second and third trimesters: Risk of neonatal respiratory depression, irritability, and withdrawal if used near term. Avoid in third trimester due to risk of premature closure of ductus arteriosus (codeine component).
Excreted into breast milk in low concentrations (M/P ratio approximately 0.10). Considered compatible with breastfeeding; however, use lowest effective dose for shortest duration given potential for neonatal adverse effects (e.g., thrombocytopenia, renal dysfunction).
Codeine is excreted in breast milk (M/P ratio ~2.5); risk of neonatal opioid toxicity (CNS depression). Diphenhydramine may inhibit lactation and cause drowsiness in infant. Contraindicated during breastfeeding due to possible severe adverse reactions in neonates.
No standard dose adjustments recommended; however, due to increased plasma volume and metabolism in pregnancy, higher doses may be required to achieve therapeutic effect. Avoid near term.
No established safe dose during pregnancy; avoid use. If unavoidable, use lowest effective dose for shortest duration. Pharmacokinetic changes (increased clearance, volume of distribution) may require dose adjustment, but due to risks, alternative therapy is recommended.
ACEPHEN (acetaminophen) is commonly used for mild to moderate pain and fever. Avoid exceeding 4 g/day in adults to prevent hepatotoxicity. In patients with hepatic impairment, reduce maximum daily dose to 2 g. Consider acetylcysteine for overdose. Onset of action is 15-30 minutes orally.
Ambien (zolpidem) is a non-benzodiazepine sedative-hypnotic used primarily for short-term insomnia. Avoid co-administration with alcohol or other CNS depressants. Use the lowest effective dose, especially in elderly patients, due to increased risk of falls and cognitive impairment. Monitor for complex sleep behaviors (e.g., sleep-driving). Tablet should be taken immediately before bedtime, not with or after a meal to avoid delayed onset.
Do not exceed 4000 mg (4 grams) in 24 hours.,Avoid drinking alcohol while taking this medication.,Do not combine with other products containing acetaminophen.,Take with food if stomach upset occurs.,Seek immediate medical help if you experience symptoms of liver damage: yellowing of skin/eyes, dark urine, severe abdominal pain.
Take zolpidem exactly as prescribed, only when you have at least 7-8 hours to devote to sleep.,Do not take zolpidem with alcohol or other sedatives as this can cause severe drowsiness and dangerous side effects.,Avoid driving or operating machinery the morning after taking zolpidem, as it may cause drowsiness, dizziness, or impaired coordination.,Report any unusual behaviors during sleep, such as walking, eating, or driving, to your doctor immediately.,Do not crush, chew, or split the extended-release tablets; swallow them whole.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACEPHEN vs AMBENYL, answered by our medical review team.
ACEPHEN is a Non-Opioid Analgesic that works by ACEPHEN (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, particularly COX-2, reducing prostaglandin synthesis. It has weak peripheral COX inhibition and minimal anti-inflammatory effect.. AMBENYL is a Antitussive/Antihistamine Combination that works by AMBENYL is a combination product containing codeine (opioid agonist) and bromodiphenhydramine (antihistamine). Codeine binds to mu-opioid receptors in the CNS, inhibiting ascending pain pathways and altering pain perception; bromodiphenhydramine antagonizes histamine H1 receptors, producing antitussive and sedative effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACEPHEN and AMBENYL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACEPHEN is: 325-650 mg orally every 4-6 hours as needed; maximum 4 g/day.. The standard adult dose of AMBENYL is: Each 5 m L contains codeine phosphate 10 mg and diphenhydramine hydrochloride 12.5 mg. Adults: 10 m L (2 teaspoonfuls) orally every 4-6 hours as needed; maximum 40 m L per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACEPHEN and AMBENYL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACEPHEN is classified as Category C. Pregnancy Category C. First trimester: potential risk of neural tube defects and orofacial clefts (limited human data, animal studies show embryotoxicity). Second and third trimest. AMBENYL is classified as Category C. FDA Pregnancy Category C. First trimester: Limited data; potential for fetal malformations (cleft palate, cardiac defects) based on animal studies with high-dose antihistamines. Se. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.